ArticleJTO clinical and research reports2026
Lung Cancer Screening-Eligible Population From 2000 to 2050 in Argentina: A Simulation Study Brief Report.
Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Introduction: In Argentina, lung cancer remains the leading cause of cancer death. However, the National Cancer Institute lacks formal lung cancer screening (LCS) recommendations. We projected LCS-eligible populations from 2000 to 2050 under varying screening criteria. Methods: We used Argentina's version of the Cancer Intervention and Surveillance Modeling Network Smoking History Generator. This microsimulation model generates cohort-specific smoking histories by age and sex. We projected the number of LCS-eligible individuals in Argentina from 2000 to 2050 under (1) the U.S. Preventive Services Task Force 2021 criteria (ages 50-80 y, ≥20 pack-years, currently smoke or have quit within the past 15 y) and (2) the U.S. National Lung Screening Trial criteria (ages 55-74, ≥30 pack-years, currently smoke or have quit within the past 15 y). Results: Under the U.S. Preventive Services Task Force 2021 criteria, LCS-eligible individuals are projected to plateau at 1.6 million between 2018 and 2036, declining to 1.3 million by 2050; the proportion of eligible individuals aged 50 to 80 years is expected to fall from 15.1% in 2018 to 7.8% in 2050 amid population growth and declining smoking rates. Under the National Lung Screening Trial criteria, eligibility peaks at 0.8 million in 2016 and declines to 0.6 million by 2050; the proportion of eligible individuals aged 55 to 74 years decreases from 11.2% to 5.3% over this period. Conclusions: Demand for LCS will gradually decrease as fewer individuals meet the eligibility criteria. Despite projected declines, between 0.5 million and more than 1 million Argentinians will remain LCS eligible by mid-century, supporting consideration of a national screening program to reduce lung cancer mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.